Incretin Effect in Lean and Obese Subjects

The Impact of Obesity and Insulin Resistance on the Incretin Effect in Patients With Type 2 Diabetes and Healthy Subjects

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00803296

Acronym

BMI-INK

Enrollment

Registered

2008-12-05

Start date

2006-01-31

Completion date

2008-06-30

Last updated

2010-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Incretin Effect, Insulin Resistance, Type 2 Diabetes

Brief summary

The incretin effect is markedly reduced in patients with type 2 diabetes. Data support the notion that this deficiency is a consequence of the diabetic state. However, the impact of insulin resistance on the incretin effect in obese individuals who uphold a normal glucose tolerance (NGT) despite their insulin resistant state remains to be elucidated. The primary aim of the present study is to evaluate the separate impact of one of the cornerstones of type 2 diabetic pathophysiology, namely insulin resistance, on the incretin effect in lean and obese patients with type 2 diabetes and in two matched normal-glucose tolerant groups of healthy control subjects.

Interventions

OTHEROral glucose tolerance test (OGTT)

OTHERIsoglycemic intravenous glucose infusion

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

MALE

Age

18 Years to 70 Years

Healthy volunteers

Yes

Inclusion criteria

* Diagnosed with type 2 diabetes for at least 3 months * Normal blood hemoglobin * Informed consent

Exclusion criteria

* Liver disease * Diabetic nephropathy * Treatment with medication that can not be stopped for 12 hours

Design outcomes

Primary

Measure	Time frame
Incretin effect	2 days

Secondary

Measure	Time frame
Insulin resistance	2 days

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026